Adaptimmune Therapeutics (NASDAQ:ADAP) Director Peter A. Thompson sold 10,300 shares of the business’s stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $13.50, for a total transaction of $139,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ ADAP opened at $12.02 on Friday. The company has a market cap of $1.16 billion, a P/E ratio of -15.03 and a beta of 1.17. Adaptimmune Therapeutics has a 52 week low of $12.39 and a 52 week high of $12.95.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The firm had revenue of $4.27 million for the quarter, compared to the consensus estimate of $9.38 million. Adaptimmune Therapeutics had a negative return on equity of 32.57% and a negative net margin of 160.83%. analysts forecast that Adaptimmune Therapeutics will post -0.87 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. NEA Management Company LLC raised its stake in shares of Adaptimmune Therapeutics by 10.9% during the 1st quarter. NEA Management Company LLC now owns 13,332,611 shares of the biotechnology company’s stock worth $149,725,000 after acquiring an additional 1,306,612 shares in the last quarter. BlackRock Inc. raised its stake in shares of Adaptimmune Therapeutics by 43,632.6% during the 4th quarter. BlackRock Inc. now owns 787,187 shares of the biotechnology company’s stock worth $5,258,000 after acquiring an additional 785,387 shares in the last quarter. Millennium Management LLC raised its stake in shares of Adaptimmune Therapeutics by 83.4% during the 1st quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock worth $16,594,000 after acquiring an additional 672,046 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics by 33.6% during the 1st quarter. Baillie Gifford & Co. now owns 2,565,409 shares of the biotechnology company’s stock worth $28,810,000 after acquiring an additional 644,816 shares in the last quarter. Finally, Foresite Capital Management II LLC bought a new position in shares of Adaptimmune Therapeutics during the 1st quarter worth approximately $4,492,000. Hedge funds and other institutional investors own 55.78% of the company’s stock.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.